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ABSTRACT: Most tumor-targeted drug delivery systems must overcome a
large variety of physiological barriers before reaching the tumor site and
diffuse through the tight network of tumor cells. Many studies focus on
optimizing the first part, the accumulation of drug carriers at the tumor site,
ignoring the penetration efficiency, i.e., a measure of the ability of a drug
delivery system to overcome tumor surface adherence and uptake. We used
three-dimensional (3D) tumor spheroids in combination with light-sheet
fluorescence microscopy in a head-to-head comparison of a variety of
commonly used lipid-based nanoparticles, including liposomes, PEGylated
liposomes, lipoplexes, and reconstituted high-density lipoproteins (rHDL).
Whilst PEGylation of liposomes only had minor effects on the penetration efficiency, we show that lipoplexes are mainly associated
with the periphery of tumor spheroids, possibly due to their positive surface charge, leading to fusion with the cells at the spheroid
surface or aggregation. Surprisingly, the rHDL showed significantly higher penetration efficiency and high accumulation inside the
spheroid. While these findings indeed could be relevant when designing novel drug delivery systems based on lipid-based
nanoparticles, we stress that the used platform and the detailed image analysis are a versatile tool for in vitro studies of the
penetration efficiency of nanoparticles in tumors.
1. INTRODUCTION
Over the last decades, nanoparticles (NPs) have been
established as promising drug carriers for cancer therapy.1−3
The advantages of using NPs as drug carriers include specific
targeting, enhanced drug stability, and accumulation in the
tumor tissue relative to free drugs.4,5 Especially lipid-based NPs
are attractive due to their high biocompatibility compared to
other nanosized drug carriers, e.g., gold NPs or quantum
dots.2,3 Most often, clinically approved lipid-based drug
delivery systems rely on passive accumulation at the tumor
site.3,4,6
The majority of studies on NP drug delivery focus on the
accumulation of NPs in the tumor tissue (through biodis-
tribution studies) and are less concerned with the penetration
profile of the NPs into the tumor. We emphasize that the
penetration efficiency of the NPs is an important parameter as
the therapeutic efficiency could be limited when the drug is
only delivered to the outermost cells of the tumor.7,8 Whilst it
is well established that NP penetration depends on the
physicochemical properties of the NPs, e.g., size,9−12 a detailed
head-to-head comparison of the penetration of a broad
selection of lipid-based NPs is still wanted to learn which
kind of lipid-based NPs to use for a certain drug candidate.
Hence, this study provides a comparative investigation of the
penetration efficiencies of liposomes (Lip), PEGylated lip-
osomes (PEG-Lip), reconstituted high-density lipoproteins
(rHDL), and lipoplexes (LPX), which have all reached clinical
trials.2,13,14 As a non-lipid control, we used polystyrene
nanoparticles (PNP) (Figure 1). Briefly, liposomes (Lip and
PEG-Lip) are some of the most commonly used drug carriers.
They are spherical vesicles comprising a lipid bilayer and an
aqueous core, while surface grafting of polyethylene glycol
(PEG) is frequently used to increase their blood circulation
time.2,15,16 LPX are complexes of nucleic acids that are
stabilized by cationic lipids13 and are usually used for gene-
targeting applications.2 The rHDL are biomimetic particles
similar to the endogenous high-density lipoproteins (HDL), a
natural lipid transporter in the body;14 hence, rHDL are
promising drug delivery carriers for various applications.17
There are several variants of the rHDL/HDL-mimicking
particles,14,18 and in this study, we used the ∼10 nm-sized
discoidal rHDL consisting of a lipid bilayer stabilized at the
edge by two apolipoproteins A-I (apoA-I).
The lipid-based NPs used here differ in several aspects like
(i) size, (ii) surface charge, (iii) surface chemistry, and (iv)
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targeting mechanisms. For the latter, only rHDL are believed
to be actively targeting as they are recognized by the scavenger
receptor class B type 1 (SR-BI) that is overexpressed in many
types of cancer cells,14,19 including the U87-MG brain cancer
cells used in this study.20
To investigate the NP uptake and penetration, we used an in
vitro three-dimensional (3D) tumor spheroid model,21,22
which is a well-established drug screening system.23−25 Even
though this simple system is grown from monocultures, it still
preserves the essential features present in cancer tumors in
vivo, i.e., rapid proliferation at the surface and slow
metabolism, or necrosis, in the center of spheroids.26 The
majority of studies of NP distributions in tumor spheroids use
tumor spheroid fixation,27−35 often in combination with
histological sectioning.7,36−39 Nevertheless, there are also
reports of NP penetration in live tumor spheroids using
confocal-scanning microscopy.40−50 Live imaging of NP-
treated tumor spheroids ensures that the studied NPs preserve
localization, stability, and emission wavelength,51,52 as
indicated for semiconducting NPs.53 However, the high
scattering and absorption of a live tissue54 limits the imaging
depth. Thus, to overcome these constraints, we used an Airy
beam light-sheet microscope55,56 that allows for optical
sectioning with little bleaching or photodamage.57 With this
setup, we combine deep imaging of NPs with single-cell
resolution of tumor spheroids of hundreds of micrometers.27,58
This study is a head-to-head comparison of the penetration
efficiencies of several lipid-based NPs commonly used for drug
delivery. We use a 3D tumor spheroid model in combination
with optical sectioning and a custom-made analysis procedure,
and we find that clustering on the tumor spheroid surface and
penetration efficiency vary significantly among the tested lipid-
based NP types. This in vitro platform can easily be adapted to
study the penetration of a large variety of fluorescently labeled
NPs. Hence, we provide an important tool to screen and
optimize the penetration efficiency of NPs before conducting
more complex in vivo studies.
2. MATERIALS AND METHODS
2.1. Preparation of NPs. 2.1.1. Materials. The lipids 1,2-
dipalmitoyl-sn-glycero-3-phosphocholine (DPPC), cholesterol,
1,2-dioleoyl-3-trimethylammonium-propane (chloride salt)
(DOTAP), and 1,2-dioleoyl-sn-glycero-3-phosphoethanol-
amine-N-[amino(polyethylene glycol)-2000] (ammonium
salt) (DOPE-PEG2k) were supplied from Avanti Polar Lipids.
The lipophilic carbocyanine dye 1,1′-dioctadecyl-3,3,3′,3′-
tetramethylindocarbocyanine perchlorate (DiI) was supplied
from Thermo Fisher Scientific. The CpG ODN 2395 was
supplied from Invivogen. The stealth liposome mix (consisting
of hydrogenated soy L-α-phosphatidylcholine (HSPC), choles-
terol, and DSPE-PEG2k in a weight ratio of 3:1:1) was
acquired from Lipoid GmbH (Germany). Reagents for the
buffers used for preparation of the NPs (phosphate-buffered
saline (PBS), sodium chloride, sodium citrate, and Hepes,
glucose, and sodium cholate hydrate), 99.9% absolute ethanol,
and tert-Butanol were all supplied from Sigma-Aldrich
(Denmark).
2.1.2. Liposomes/PEGylated Liposomes. Lip were prepared
with DPPC/cholesterol/DiI in a molar ratio of (61.3:38.2:0.5),
while PEG-Lip were prepared from the stealth liposome mix
HSPC/cholesterol/DSPE-PEG (56.6:38.2:5.2) supplied with
0.5 mol % DiI. Initially, the lipids were dissolved in tert-
butanol/MilliQ (9:1), snap-frozen in liquid nitrogen, and
freeze-dried overnight using a Scanvac Coolsafe lyophilizer
(Labogene, Denmark). The dry lipids were rehydrated in PBS
to a total lipid concentration of 10 mM and put under 65 °C
heating and magnetic stirring for 1 h. The size of the liposomes
was controlled by extruding 21 times through Whatman filters
(GE Healthcare, U.K.) with a pore size of 100 nm using a
Mini-Extruder from Avanti Polar Lipids. The liposome
suspension was transferred to a glass vial and stored at 4 °C.
2.1.3. Lipoplexes. LPX were prepared by the ethanol-
injection method. They were formulated with cholesterol/
DOTAP/DOPE-PEG2k/DiI (49.5:49:1:0.5) and CpG ODN
2395 (single-stranded synthetic DNA) as the encapsulated
nucleic acid. Initially, the lipids were dissolved in 99.9%
absolute ethanol, and CpG was diluted in a citrate buffer, pH 5.
The lipid solution was mixed into the CpG solution under
vigorous vortexing, yielding a DOTAP/CpG (8:1). Immedi-
ately after mixing, the mixture was diluted by adding twice the
volume of buffered saline (0.3 M sodium chloride, 20 mM
sodium citrate, pH 6.0). To remove excess ethanol, the
solution was then dialyzed for 24 h using cassettes with 3.5k
MWCO (Thermo Fisher Scientific) against 300 mM Hepes
and 5% glucose buffer (pH 7.4) with two buffer exchanges.
After dialysis, the LPX solution was transferred to amicon spin
filters (MWCO 10 000) in 15 mL tubes and centrifuged three
times at 4000g and 4 °C for 10 min. Between each cycle, the
volume was replenished by adding 300 mM Hepes and 5%
glucose buffer (pH 7.4) to ensure the removal of unbound
CpG. After washing, the LPX solution (10 mM total lipid
concentration) was transferred to a new vial and allowed to
equilibrate at room temperature for 30 min. The LPX were
stored at 4 °C and used within 4 weeks after preparation.
2.1.4. rHDL. The lipids DPPC/DiI (99.5:0.5) were dissolved
in tert-butanol/MilliQ (9:1) before freeze-drying overnight.
ApoA-I (purified from human plasma as described else-
where19) dissolved in PBS containing 20 mM cholate was
added to the lipid mixture such that it yielded a protein/lipid
Figure 1. Overview of the NPs in this study. The sketch of the lipid-based NPs used in this study: PEGylated liposomes (PEG-Lip), liposomes
(Lip), lipoplexes (LPX), and reconstituted high-density lipoproteins (rHDL), consisting of lipid bilayers (blue), aqueous cores (white), fluorescent
markers (red), nucleic acids (purple), and apoA-I proteins (green). For comparison, we also used a non-lipid particle (PNP).
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molar ratio of 100 and a total lipid concentration of 5 mM.
The solution was heated to 41 °C for approximately 1 h to
ensure that the lipids were dissolved. Subsequently, Bio-Beads
from Bio-Rad (Denmark) were added to remove the cholate
and induce the self-assembly of the rHDL. The sample was
incubated overnight with the Bio-Beads that were removed
afterward by spinning the liquid from a 2 mL Eppendorf tube
with a perforated hole into a falcon tube. The sample was
stored at 4 °C.
2.2. Characterization of the NPs. All lipid-based NPs
were fluorescently labeled using 0.5 mol % DiI fluorophore
(549/565 nm). They were diluted in PBS, such that they
contained a similar amount of fluorophores, as estimated by
absorbance (NanoDrop 2000/2000c Spectrophotometer,
Thermo Fisher Scientific), (Supporting Information Figure
S2), and were further diluted 10× in an imaging medium (see
Section 2.4 ) when added to the spheroids.
The fluorescently labeled (580/605 nm) anionic polystyrene
carboxylate-modified nanoparticles (Thermo Fisher, Lot No. =
1922891) were sonicated for 10 min and were diluted in an
imaging medium (see Section 2.4 section) to a final
concentration of 1.7 × 1011 particles/mL.
The hydrodynamic diameters of the NPs were measured by
dynamic light scattering (DLS) on a ZetaSizer Nano ZS
(Malvern Instruments, U.K.) over an average of three runs of
10−15 cycles. The results were estimated by number [%]. The
ζ-potential was obtained by the same instrument using a
universal “Dip” Cell (Malvern Panalytical, U.K.) and was
estimated with an average of three runs with an automatically
determined number of cycles (10−100 cycles). Before the ζ-
potential measurements, the samples were diluted 25× in a
buffer containing 10 mM Hepes and 5% glucose (pH 7.4). For
both the size and ζ-potential measurements, a distribution was
obtained from each run/cycle with mean and standard
deviation (SD). In Table 1, we present the average of the
means and average of the SD from the three runs.
2.3. Cell Culture. Gliosblastoma multiforme U87-MG cells
were cultured in high-glucose Dulbecco’s-modified Eagle’s
Medium (DMEM) supplemented with 10% fetal bovine serum
(FBS) and 1% (100 units/mL penicillin and 100 μg/mL
streptomycin), all from Gibco.
2.3.1. Gravitation-Assisted Spheroid Formation. Five
hundred cells were seeded in each round-bottom ultralow
attachment of 96 wells (Corning Costar) in a volume of 100
μL DMEM and incubated for 72 h (37° C, 5% CO2, and 100%
humidity). After 72 h, the spheroids reached a radius of 134 ±
10 μm (mean ± SD, N = 19).
2.4. Sample Preparation. For imaging, the culture
medium was replaced by phenol red-free DMEM (FluoroBrite,
Gibco) without serum to minimize the noise. Fully formed
spheroids were rinsed three times with imaging medium and
were treated with nanoparticles in a fresh imaging medium for
5 h. After 3 h of incubation, the spheroids were nuclear-labeled
by supplementing the wells with a cell-permeable nucleic acid
stain (SYTO13, Invitrogen; 488/509 nm). Although the
nuclear stain is a high-performance dye, it causes phototoxicity
within 3 h,59 which restricts live-cell imaging. Spheroids were
washed three times in PBS (Gibco) and were then immersed
in a fresh imaging medium. The spheroids were embedded in
1% low-melt agarose (NuSieve GTG Agarose; Lonza, Rock-
land, ME), were transferred separately in fluorinated ethylene
propylene (FEP) tubes (inner diameter 0.8 mm, outer
diameter 1.6 mm) (Bohlender), and were mounted on the
microscope.
2.5. Live Spheroid Imaging. We used an Aurora airy
light-sheet microscope (M Squared) with a M2 filter cube with
one objective for illumination (UMPlanFL N 10×/0.30 W)
and one for detection (UMPlanFL N 20×/0.50 W), each with
a 3.5 mm working distance. The light sheet was equipped with
a blue (488 nm) and a yellow (570 nm) laser. The light sheet
allowed deep sample penetration and high axial resolution over
an extended field view (600 mm × 600 mm). The emitted light
was collected through a band-pass filter (520−540 nm) and
low-pass filter (>570 nm) for the 488 and 561 nm laser beams,
respectively. Two stacks of images were recorded sequentially,
one for the nuclear stain and one for the nanoparticle stain in
steps of 0.4 μm in the axial direction using the build Aurora
Alpha acquisition software. The laser intensity and exposure
were kept constant among experiments, which were performed
in room temperature with minimized background light.
2.6. Image Analysis. To measure the fluorescence
intensity versus depth of the spheroid, we analyzed the
cross-sections and quantified the intensity with a combination
of Fiji plugins and custom-made Matlab routines. As our
spheroids on average were 300 μm in diameter and the step
size in the axial direction was 0.4 μm, the measured intensities
of our cross-sections was averaged over 100 frames (which
corresponds to 40 μm). We estimated the variation of the
radius over this band to be less than the variations in Rθ in the
imaging plane. The obtained average cross-sections were
analyzed to obtain the mean intensities as in eq 1.
2.6.1. Statistics. Unless otherwise stated, data are shown as
mean ± standard deviation (SD) or SD of the mean (SEM), N
≥ 3. To assess statistical significance, analysis of variance
(ANOVA, one-way) was performed for comparison of means,
followed by Tukey’s post hoc test. Upon comparison to the α
level of 5%, a p-value of <0.05 was considered statistically
significant.
3. RESULTS AND DISCUSSION
To study the penetration efficiency of the NPs, we used a brain
cancer tumor spheroid model grown from a seed of (∼200
cells/well) U87-MG cells in round-bottom ultralow attach-
ment wells. While negatively charged coating impedes cell
attachment to the wells, gravitation assists agglomeration
(Figure 2A).60,61 After the initial spheroid formation, the
growth rate was estimated to be ∼40 μm/day under our
experimental conditions. Spheroids were harvested after 3
days, where they had reached a final radius of 134 ± 10 μm
(mean ± SD, N = 19) and a density of about 3 × 10−4 cells/μ
m3. All spheroids were confirmed to attain similar morpho-
logical characteristics, e.g., ellipticity of 0.5 ± 0.1 (Figure S3).
Table 1. Characterization of the NPs Used in the Studya
Lip PEG-Lip LPX rHDL PNP
size (nm) 114 ± 35.9 112 ± 25.9 77.2 ± 28.7 8.70 ± 1.70 24.1 ± 6.77
ζ-potential (mV) 0.827 ± 6.24 −8.83 ± 9.43 9.96 ± 4.43 −9.39 ± 5.27 −31.0 ± 20.1
aThe mean size is based on the number (%) from dynamic light scattering measurements. Data represent mean ± SD.
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In general, cancer spheroids have an outermost layer of
proliferating cells, an intermediate quiescent region, and
sometimes even a necrotic core.26 The cancer spheroids used
in this study, however, are reported to have high viability even
in the core region.62
3.1. Preparation and Characterization of the NPs. The
lipid-based NPs (Figure 1) were prepared using standard
methods as described in detail elsewhere for liposomes,63
LPX,64 and rHDL.19 Briefly, Lip and PEG-Lip were formed by
hydration of freeze-dried lipids, followed by extrusion through
a 100 nm filter. LPX were prepared by the ethanol-injection
technique, where lipids dissolved in ethanol were rapidly
injected into an aqueous buffer containing the nucleic acids
CpG. rHDL were prepared by the detergent depletion method,
where lipids were dissolved with detergents that were
subsequently depleted using Bio-Beads in the presence of the
apolipoprotein A-I (apoA-I) to induce the self-assembly of
rHDL. The NPs’ size and surface charge, i.e., ζ-potential, are
listed in Table 1.
The distribution and penetration of the lipid-based NPs
were studied by detection of the DiI in the NPs. Besides being
used as the fluorescent label, the lipid-conjugated DiI can also
be considered as a model of lipid-conjugated drugs
incorporated into the NPs. We confirmed that DiI was stably
incorporated into the lipid-based NPs (Supporting Informa-
tion Figure S1), as consistent with previous studies using
similar types of fluorophores.15,19 We emphasize that all of the
lipid-based NPs were prepared with equal mol% of
fluorophores (0.5% DiI), and that the concentration of the
NPs was adjusted such that the amount of fluorophores (based
on absorbance) was equal in each sample (Supporting
Information Figure S2). Thus, we assume that the lipid
concentration was the same in each sample. Note that due to
the different sizes of the lipid-based NPs, this implies that the
particle concentration varied between samples.
3.2. Distribution of NPs in Tumor Spheroids. NP-
treated tumor spheroids were optically sectioned (Figure
2B,C) in 400 nm steps to measure the fluorescence intensity
on planar cross-sections of the spheroids. Notably, the
intensity of the nuclear stain gradually decreased toward the
center of the spheroids, which is likely explained by the
diffusion gradient7 and effects from attenuation of the exciting/
emitting light at increasing depths.57 Interestingly, the cross-
sections (Figure 3) show a clear difference in the distribution
of the different NPs in the tumor spheroids. While spheroids
treated with Lip, PEG-Lip, rHDL, and PNP exhibited
fluorescence intensity distributed across the whole cross-
section (though with varying intensity), LPX accumulated
primarily at the spheroid surface. Areas with augmented
fluorescence were observed for rHDL, Lip, and LPX, and while
these areas were confined to the spheroids’ surface for LPX and
Lip, they also appeared deeper in the spheroids for rHDL. The
augmented fluorescence likely corresponds to either aggrega-
tion of particles or high local cellular uptake of NPs. In
particular, LPX, due to positive surface charges, might
effectively fuse with the outermost cells or aggregate in the
culture medium (at 37 °C), since LPX is considered relatively
unstable without PEGylation.65 Aggregation of LPX would
likely render their size larger than the pores in the tumors,
thereby impeding penetration, while adherence to the surface
of the cells or cellular uptake prevents aggregated LPX from
being washed out before imaging. Similarly, Lip are considered
more prone to aggregation than PEG-Lip.2,66,67 However, in
contrast to the initially smaller LPX, the neutral surface charge
of the Lip possibly allowed them to penetrate deeper into the
tumor due to inferior NP-cell interactions, before aggregation
or cellular uptake. On the other hand, rHDL showed enhanced
accumulation at much greater penetration depths. This could
in part be ascribed to the smaller size of rHDL, allowing them
to pass more easily through the interstitial space between the
cells, like in the case of PNP.
3.3. NP Tumor Spheroid Penetration. The imaging of a
dense spheroid is in brief limited by two conditions: (i) the
attenuation of the fluorescence emission and (ii) the
attenuation of the exciting laser through the spheroid. To
balance (i), we did not use the cross-section from the spheroid
equator but instead a cross-section closer to the imaging
objective (emission Figure 2B) at a depth of 100−140 μm.
Therefore, the measured intensities were averaged over 40 μm,
which corresponds to 100 frames (Supporting Information
Figure S4). Furthermore, to redeem the effect of (ii), we
restricted our analysis to the half of the cross-section closest to
the exciting laser (Figure 2D) and to a maximum depth of 80
μm.
From the masks of the averaged cross-sections, we defined
the spheroid surface (d = 0 μm) as the maximum intensity
depth of the nuclear stain. As the surface of the spheroid is
rough, the radius of the spheroid, Rθ, changes in respect to the
polar angle, θ (Figure 2D). Therefore, the intensity at a specific
depth, d, of the averaged cross-section was quantified as
follows68
Figure 2. Overview of the experimental setup. (A) Illustration of
gravitation-assisted tumor spheroid growth. (B) Sketch of a spheroid
mounted for imaging in an Airy beam light-sheet microscope, with
one objective for the (yellow) light sheet (excitation) and one for
collection of the emitted light (emission). (C) Close-up of a spheroid
mounted in a tube for imaging. (D) Example of a spheroid’s cross-
section mask, where the radial vector from the origin goes to the
mask’s boundary; Rθ varies in length with respect to the polar angle θ.
The mask boundary was slightly larger than the spheroid’s surface
(gray contour) and the blue vector indicates the tumor depth, d. We
restricted our analysis to the half-spheroid closest to the light-sheet
objective (excitation).
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We found the normalized intensity profiles ⟨I⟩ averaged over
all N spheroids of the nuclear stain (gray) and the investigated
NPs as a function of the spheroid depth d (Figure 4).
Regardless of the natural variations among the spheroids, the
penetration profiles were specific for each type of NPs.
Consistent with the cross-section images (Figure 3), we
observed a gradual decrease in the nuclear stain’s intensity over
d. Even though individual nuclei cannot be distinguished at
penetration depths greater than ∼50 μm, it has been previously
shown that U87-MG spheroids of similar sizes have uniform
densities.62 Furthermore, we observed that both rHDL and
LPX exhibited high surface adhesion. However, LPX remained
at the spheroid rim, while all of the other NPs penetrated more
effectively toward the center of the tumor spheroid.
The penetration depth can be interpreted by the declination
of the surface intensity by half d1/2 for the averaged profile.
This measure confirmed the limited penetration depth of LPX,
d1/2 = 26 μm, in contrast to the larger penetration depths of
Figure 3. Cross-sections of U87-MG tumor spheroids treated with NPs. The pseudocolored images are representative examples of optical sections
from spheroids at different depths in the axial direction (40−200 μm). The spheroids were all nuclear stained (green) and treated with NPs (red):
Lip, PEG-Lip, rHDL, PNP, or LPX, for 5 h. The images have uneven contrast settings between the different NPs, and the scale bars correspond to
100 μm.
Figure 4. Penetration of NPs in U87-MG tumor spheroids. The
normalized average intensity of NP fluorescence versus tumor
spheroid depth, d. The intensity was averaged over all treated
spheroids and normalized with the surface intensity (the surface was
defined from the nuclear stain). All spheroids were exposed to both
nuclear stain (gray, N = 19) and NPs: Lip (blue, N = 3), PEG-Lip
(red, N = 5), rHDL (yellow, N = 4), PNP (green, N = 4), and LPX
(purple, N = 3). The shaded area corresponds to the tumor spheroid
surface, and error bars correspond to one SEM.
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Lip, d1/2 = 39 μm, and PEG-Lip, d1/2 = 67 μm. The larger
penetration depth of PEG-Lip relative to Lip could be
attributed to reduced interactions with the cells due the
PEGylation, thus allowing for increased penetration into the
tumor spheroid, as also reported elsewhere for PEGylated
NPs.7 Though the d1/2 indeed is a descriptive measure, it is not
instrumental for the analysis of penetration profiles that differ
from an exponential decay. For instance, rHDL had a unique
secondary peak (d = 80 μm). Furthermore, PNP did not
reduce the fluorescence intensity by half at the measured
depths, although the intensity gradually decreased after the first
surface cell layers.
The up-concentration in depth observed for rHDL might be
explained by aggregation. Although rHDL are relatively
stable,69,70 rHDL aggregation might occur due to varying
environmental conditions toward the spheroid core. For
example, the spheroid core is slightly more acidic relative to
the surface due to the increased lactate production from the
oxygen-deficient cells,71 and the acidic conditions could
potentially cause the HDL-associated apoA-I to unfold.72
Interestingly, the PNP (∼24 nm) did not accumulate toward
the spheroids’ center, though they seemingly also diffused
throughout the tumor spheroids. This further confirms that the
rHDL distribution in the spheroids is controlled by additional
parameters besides size.
3.4. Penetration Efficiency. To further quantify the
ability of the various NPs to penetrate the tumor spheroid, we
defined the penetration efficiency as the following ratio
∑δ = ⟨ ⟩⟨ ⟩=N
I
I
1
i
N
1
in
out (3)
where N is the number of spheroids, ⟨I⟩out is the average NP
fluorescence at shallow depths (0 μm < d < 20 μm), and ⟨I⟩in is
the average intensity deeper in the spheroids (60 μm < d < 80
μm). A uniform distribution of NPs within the spheroid would
yield a δ close to 1 convoluted with an exponential-like decay
due to the attenuation of the laser light, etc. As the penetration
efficiency δ of the nuclear stain reflects the diffusion gradient in
combination with the attenuating factors, it can be used to
assess the homogeneity between tumor spheroids. The
consistent δ values for the nuclear stain (Figure 5) confirmed
that the tumor spheroids were uniform in morphology and
size. The penetration efficiency of the NPs (Figure 5) generally
followed the trends observed from the cross-sections (Figure
3) and penetration profiles (Figure 4). Only LPX had lower δ
than the nuclear stain and significantly lower than Lip (p <
0.04), PEG-Lip (p = 0.001), and PNP (p = 0.002), since they
were mainly associated or were taken up by the outermost
cells. The rHDL showed the highest penetration efficiency δ,
which was significantly larger than Lip (p = 0.02), nuclear
stain, and LPX (p < 0.0001, both). This is likely due to a
combination of their small size, allowing them to easily diffuse
through intercellular spaces of the tumor spheroids, and the
surprising augmented accumulation of rHDL deeper in the
spheroid.
To evaluate if NPs were taken up by the cells or simply
adhered to their surface, we imaged the surface cells of the
spheroid individually (Figure 6). As these images show single
sheets in the imaging stacks (0.4 μm thickness) inside the
more than 10 μm cells, the NP fluorescence (red) measured in
proximity to the nucleus (green) is likely to be internalized
NPs. These results are indicative of a view where all NPs were
internalized (passively or actively) but to a greater extent for
rHDL and LPX compared to Lip and PEG-Lip. Evidently,
LPX, rHDL, and Lip were not only taken up by the cells but
they also formed aggregations that adhered to the spheroid
surface (Figure 3). The effect of cell internalization on NP
penetration in tumors is disputed, as it has been found to both
reduce penetration due to depletion7 and to facilitate
penetration by transcellular transport.73
Interestingly, Lip and PEG-Lip show similar uptake by
outermost cells (Figure 6A,B) and have similar δ (p = 0.95),
though the d1/2 indicated that PEG-Lip penetrated deeper into
the spheroid. This can in part be explained by the measured
intensity peak of PEG-Lip just beneath the tumor spheroid
surface (Figure 4). Hence, the PEG-Lip apparently overcame
the adherence to the spheroid surface and penetrated the first
cell layers efficiently, while only a limited amount reached
deeper into the spheroid. We speculate that their PEGylation
reduces the interactions between PEG-Lip and the cell
membrane74 to allow rapid diffusion through the sphe-
roid,7,42,75 in contrast to the less negatively charged/non-
PEGylated Lip and to the slightly positively charged LPX.
3.5. Effect of the NP Design on the Penetration
Efficiency. The penetration efficiency is an interplay between
the NP design, tumor morphology, and cell internalization
sensitivity.9,12 We found that LPX exhibited a very different
penetration efficiency than Lip and PEG-Lip despite their
similar size (∼100 nm). This might be attributed to the
positive surface charge of LPX causing fusion-based uptake by
the outermost cells (Figure 6) and lower stability of the LPX.
Figure 5. Boxplot of the penetration efficiency, δ, of nanoparticles in
U87-MG tumor spheroids. The penetration efficiency is the ratio
between the average fluorescence of the outermost band (0−20 μm
depth) and an inner band (60−80 μm depth).
Figure 6. Uptake of NPs by spheroid surface cells. Representative
optical sections of cells on the surface. Overlay of pseudocolored
images of nuclear-stained cells (green) on the spheroids’ surface,
treated with the various lipid-based NPs (red): PEG-Lip (A), Lip (B),
rHDL (C), and LPX (D). Intensity and contrast levels were kept
constant, and scale bars correspond to 10 μm.
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However, the importance of the surface charge has also been
observed in other studies where charged NPs were shown to
penetrate less efficiently than neutral NPs.49,76,77
The small differences in the sizes of rHDL and PNP (∼10
nm versus ∼24 nm) might contribute to the slightly different
penetration efficiencies, as shown for other NPs.9,78 We
suggest, however, that the great accumulation of rHDL inside
the spheroid is attributed to effects from the different
environments at the spheroid core relative to the surface,
e.g., the slightly acidic environment inside the spheroid might
cause rHDL aggregation or alter the interactions between the
rHDL/apoA-I and the extracellular matrix and/or cells.79
Furthermore, viability of the cells might vary toward the core,
thus potentially affecting the NP penetration. Interestingly, Lee
et al.11 showed decreased penetration depth for NPs with
targeting ligands, as the NP binding and uptake by the
outermost cells inhibited further NP penetration into the
spheroid. As SR-BI is expressed by the cells, the rHDL could,
in principle, be actively taken up by all cells in the spheroids,
thus resulting in likewise decreased accumulation toward the
tumor center due to enhanced clearance by the outermost
cells, compared to similar-sized nontargeting NPs. In contrast,
Tang et al.30 suggested that SR-BI receptor-mediated cell
uptake of HDL-mimicking NPs in the core of the tumor
spheroid is important for enhanced penetration of the NPs.
They based this claim on the observation that PEGylation of
the HDL-mimicking NPs decreased the penetration into the
tumor spheroid, which they attribute to SR-BI interactions
being diminished by PEG. However, we emphasize that SR-BI
is presumably expressed on all of the cells in the tumor
spheroid, and we therefore suggest that additional parameters
contribute to the observed increased rHDL accumulation
toward the spheroid core.
The penetration efficiency of NPs is an important evaluation
measure of therapeutic delivery systems that aim at distributing
drugs uniformly in the tumor and must be considered together
with the equally important biodistribution of NPs, which
determines how much of the intravenously administered NPs
end up in in vivo tumor tissue compared to other organs.10
More specifically, PEGylation of liposomes is believed to be
very important for long circulation times and results in high
accumulation in the tumor due to the expected enhanced
permeability and the retention (EPR) effect.3,16 However, we
emphasize that the relevance of the EPR effect is disputed80
and that the exact relation between circulation and
biodistribution is under much debate (chapter 5 in ref 81).
We observed only slight (but not significant) difference in the
penetration efficiency between Lip and PEG-Lip. In
accordance with other in vitro studies, we observed higher
penetration efficiency of the smaller NPs (rHDL and PNP).82
In contrast in vivo, ∼100 nm is believed to be the optimal size
for uptake in tumors through the EPR effect.83 Despite their
small size, intravenously injected rHDL are reported to yield
relatively high tumor accumulation, often attributed to their
SR-BI targeting feature.30,84−86 Our results suggest that the
rHDL can be retained in the tumor, possibly as a result of the
naturally occurring gradients in the cancer spheroid; hence,
this might add to the explanation of the enhanced tumor
accumulation of rHDL. Consequently, we highlight that the
amount of NPs distributed in the tumor tissue is an interplay
between NP biodistribution and penetration efficiency.
4. CONCLUSIONS
We performed a head-to-head comparison of the penetration
efficiencies of lipid-based NPs that varied in size, surface
charge, surface chemistry, stability, and targeting ability.
Besides the direct comparison between the selected lipid-
based NPs, our findings shed light on important and relevant
effects on the penetration of NPs into tumors. While we only
observed a limited effect on the penetration efficiency from
PEGylation of liposomes, we did observe an effect of the NPs’
stability and surface charge, as indicated by the limited
penetration efficiency of LPX compared to Lip/PEG-Lip. We
also observed a high penetration efficiency for rHDL and
speculated that rHDL’s unique penetration profile is attributed
to a combination of their small size and the effects associated
with the spheroid environment. It could be relevant in future
experiments to thoroughly investigate the mechanisms that
drive the different penetration efficiencies of the NPs.
The use of light-sheet microscopy and the detailed image
analysis can be easily adapted to screen the penetration
efficiency of any fluorescent NPs in 3D tumor spheroids.
Therefore, the testing of NPs is only limited by the build-in
optics of the light-sheet microscope, i.e., lasers and detectors.
Thus, we present a powerful tool and analysis method for the
in vitro evaluation of the penetration efficiency of NPs, a
measure that can be highly relevant for the therapeutic effect of
the corresponding drug delivery system.
■ ASSOCIATED CONTENT
*sı Supporting Information
The Supporting Information is available free of charge at
https://pubs.acs.org/doi/10.1021/acsomega.0c02879.
Estimation of the dynamics of the lipid-conjugated
fluorophore label incorporated into the lipid-based NPs;
determination of the dilution of NPs required to obtain
an equal amount of fluorophore in the samples; 3D
reconstruction, distribution of ellipticities and radii;
optical cross-sections of a spheroid (PDF)
■ AUTHOR INFORMATION
Corresponding Authors
Jens B. Simonsen − DTU Health Tech, Technical University of
Denmark, 2800 Kongens Lyngby, Denmark; orcid.org/
0000-0002-2223-9464; Email: jbak@dtu.dk
Liselotte Jauffred − The Niels Bohr Institute, University of
Copenhagen, 2100 København, Denmark; Email: jauffred@
nbi.dk
Authors
Maria Niora − The Niels Bohr Institute, University of
Copenhagen, 2100 København, Denmark
Dennis Pedersbæk − DTU Health Tech, Technical University
of Denmark, 2800 Kongens Lyngby, Denmark; orcid.org/
0000-0001-8900-8954
Rasmus Münter − DTU Health Tech, Technical University of
Denmark, 2800 Kongens Lyngby, Denmark
Matilda Felicia de Val Weywadt − DTU Health Tech,
Technical University of Denmark, 2800 Kongens Lyngby,
Denmark
Younes Farhangibarooji − The Niels Bohr Institute, University
of Copenhagen, 2100 København, Denmark
ACS Omega http://pubs.acs.org/journal/acsodf Article
https://dx.doi.org/10.1021/acsomega.0c02879
ACS Omega 2020, 5, 21162−21171
21168
Thomas L. Andresen − DTU Health Tech, Technical
University of Denmark, 2800 Kongens Lyngby, Denmark;
orcid.org/0000-0002-4797-8570
Complete contact information is available at:
https://pubs.acs.org/10.1021/acsomega.0c02879
Notes
The authors declare no competing financial interest.
■ ACKNOWLEDGMENTS
L.J. acknowledges funding from the Danish National Research
Council (DNRF116) and fruitful discussions with Lene
Oddershede, Pand Petra Hammerlik.
■ REFERENCES
(1) Wang, A. Z.; Langer, R.; Farokhzad, O. C. Nanoparticle Delivery
of Cancer Drugs. Annu. Rev. Med. 2012, 63, 185−198.
(2) Puri, A.; Loomis, K.; Smith, B.; Lee, J. H.; Yavlovich, A.;
Heldman, E.; Blumenthal, R. Lipid-based nanoparticles as pharma-
ceutical drug carriers: From concepts to clinic. Crit. Rev. Ther. Drug
Carrier Syst. 2009, 26, 523−580.
(3) Yingchoncharoen, P.; Kalinowski, D. S.; Richardson, D. R. Lipid-
based drug delivery systems in cancer therapy: What is available and
what is yet to come. Pharmacol. Rev. 2016, 68, 701−787.
(4) Allen, T. M.; Cullis, P. R. Drug Delivery Systems: Entering the
Mainstream. Science 2004, 303, 1818−1822.
(5) Senapati, S.; Mahanta, A. K.; Kumar, S.; Maiti, P. Controlled
drug delivery vehicles for cancer treatment and their performance.
Signal Transduction Targeted Ther. 2018, 3, No. 7.
(6) Barenholz, Y. Doxil - The first FDA-approved nano-drug:
Lessons learned. J. Controlled Release 2012, 160, 117−134.
(7) Tchoryk, A.; Taresco, V.; Argent, R. H.; Ashford, M.; Gellert, P.
R.; Stolnik, S.; Grabowska, A.; Garnett, M. C. Penetration and Uptake
of Nanoparticles in 3D Tumor Spheroids. Bioconjugate Chem. 2019,
30, 1371−1384.
(8) Li, L.; Sun, J.; He, Z. Deep Penetration of Nanoparticulate Drug
Delivery Systems into Tumors: Challenges and Solutions. Curr. Med.
Chem. 2013, 20, 2881−2891.
(9) Cabral, H.; Matsumoto, Y.; Mizuno, K.; Chen, Q.; Murakami,
M.; Kimura, M.; Terada, Y.; Kano, M. R.; Miyazono, K.; Uesaka, M.;
et al. Others, Accumulation of sub-100 nm polymeric micelles in
poorly permeable tumours depends on size. Nat. Nanotechnol. 2011,
6, 815.
(10) Perrault, S. D.; Walkey, C.; Jennings, T.; Fischer, H. C.; Chan,
W. C. W. Mediating tumor targeting efficiency of nanoparticles
through design. Nano Lett. 2009, 9, 1909−1915.
(11) Lee, H.; Fonge, H.; Hoang, B.; Reilly, R. M.; Allen, C. The
effects of particle size and molecular targeting on the intratumoral and
subcellular distribution of polymeric nanoparticles. Mol. Pharm. 2010,
7, 1195−1208.
(12) Ernsting, M. J.; Murakami, M.; Roy, A.; Li, S.-D. Factors
controlling the pharmacokinetics, biodistribution and intratumoral
penetration of nanoparticles. J. Controlled Release 2013, 172, 782−
794.
(13) Cullis, P. R.; Hope, M. J. Lipid Nanoparticle Systems for
Enabling Gene Therapies. Mol. Ther. 2017, 25, 1467−1475.
(14) Simonsen, J. B. Evaluation of reconstituted high-density
lipoprotein (rHDL) as a drug delivery platform-a detailed survey of
rHDL particles ranging from biophysical properties to clinical
implications. Nanomed.: Nanotechnol., Biol. Med. 2016, 12, 2161−
2179.
(15) Münter, R.; Kristensen, K.; Pedersbæk, D.; Larsen, J. B.;
Simonsen, J. B.; Andresen, T. L. Dissociation of fluorescently labeled
lipids from liposomes in biological environments challenges the
interpretation of uptake studies. Nanoscale 2018, 10, 22720−22724.
(16) Allen, T. M. Liposomal Drug Formulations. Drugs 1998, 56,
747−756.
(17) Pedersbæk, D.; Jønsson, K.; Madsen, D. V.; Weller, S.; Bohn, A.
B.; Andresen, T. L.; Simonsen, J. B. A quantitative ex vivo study of the
interactions between reconstituted high-density lipoproteins and
human leukocytes. RSC Adv. 2020, 10, 3884−3894.
(18) McMahon, K. M.; Plebanek, M. P.; Thaxton, C. S. Properties of
native high-density lipoproteins inspire synthesis of actively targeted
in vivo siRNA delivery vehicles. Adv. Funct. Mater. 2016, 26, 7824−
7835.
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